Forty Seven, which is developing anti-CD47 antibodies for various cancers, raised $113 million by offering 7.0 million shares at $16, the high end of the range of $14 to $16. The company had originally planned to sell 6.7 million shares. Forty Seven plans to list on the Nasdaq under the symbol FTSV. Morgan Stanley and Credit Suisse acted as lead managers on the deal.
